癌のゲノム変異と微小環境の特徴は,疾患の結果と相乗効果の相互作用をコードする
Masroor Bayati1, Zoe P Klein1, Alexander T Bahcheli1
1University of Toronto, Canada.
Molecular cancer research : MCR
|September 3, 2025
まとめ
癌の誘発因子と免疫細胞を 13種類の癌の生存に結びつける 34の免疫ゲノム相互作用 (IGXs) を特定しました これらの発見は,ゲノムと免疫データを統合することによって,予後バイオマーカーと治療標的を明らかにします.
科学分野:
- 腫瘍学
- 免疫学
- ゲノミクス
背景:
- 癌の進行は,体内のゲノム変異と腫瘍免疫マイクロ環境 (TME) によって影響を受けます.
- 腫瘍の進化と臨床結果の形成におけるゲノム駆動因子とTME特性の相互作用は完全に理解されていません.
研究 の 目的:
- マルチオミクスデータを統合する枠組みを開発し,がんの誘発因子と臨床結果に関連するTMEの特徴の相互作用を特定する.
- 予後の可能性のある新しい免疫ゲノム相互作用 (IGXs) を発見する.
主な方法:
- マルチ経済分析フレームワーク"PACIFIC"を開発した.
- 癌を誘発する遺伝子と 免疫細胞の浸透プロフィールを 体系的に統合した
- 8500個の腫瘍を 26種類のガンで分析しました
主要な成果:
- 13種類の癌で34のIGXが特定され,特定のゲノム変異と免疫細胞レベルを患者の生存と関連付けました.
- IGXsは,独特の免疫性および免疫療法標的遺伝子発現を持つ腫瘍サブセットを定義することが判明しました.
- 乳がんのLuminal-A (MEN1 欠失および低中性粒子の) では,より低進行性生存率に関連したIGXが観察されました.
結論:
- PACIFICフレームワークは,臨床的に重要なIGXを特定するために,マルチオミックと臨床データを効果的に統合しています.
- メカニズムの研究,バイオマーカーの開発,治療の標的化のための仮説を提供する予後性IGXを発見した.
- 癌の誘発因子とTMEの特徴の同時発生パターンは,予後的な価値を持つ相乗効果の相互作用を明らかにします.
関連する概念動画
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cancer Prevention
6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.3K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancers Originate from Somatic Mutations in a Single Cell
12.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.7K
Cancer-Critical Genes I: Proto-oncogenes
9.1K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.1K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K


